Xudong Yao
- Cancer Research top 5%
- Cancer-related molecular mechanisms research 7
- MicroRNA in disease regulation 4
- Cancer, Hypoxia, and Metabolism 4
- Rheumatology top 2%
- Osteoarthritis Treatment and Mechanisms 6
- Molecular Biology top 10%
- RNA modifications and cancer 4
- Bone Metabolism and Diseases 4
- Circular RNAs in diseases 3
- Pharmacology top 5%
-
- Prostate Cancer Treatment and Research 3
- Journals
- Journal of Clinical Oncology (1 paper)The Journal of Urology (1 paper)Life Sciences (2 papers)
- Partner nations
- ChinaGermanyUnited States
In The Last Decade
Xudong Yao
35 papers receiving 1.9k citations
Hit Papers
Peers
Comparison fields: 5 of 103
- Cancer Research 613
- Rheumatology 465
- Molecular Biology 1.1k
- Pharmacology 207
- Orthopedics and Sports Medicine 104
Countries citing papers authored by Xudong Yao
This map shows the geographic impact of Xudong Yao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xudong Yao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xudong Yao more than expected).
Fields of papers citing papers by Xudong Yao
This network shows the impact of papers produced by Xudong Yao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xudong Yao. The network helps show where Xudong Yao may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Xudong Yao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Advances on immunotherapy for osteosarcomabreakdown → | 2024 | 85 |
| 2 | 2024 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 2 | |
| 5 | 2023 | 5 | |
| 6 | Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis and Activating the Nrf2 Pathwaybreakdown → | 2022 | 161 |
| 7 | 2022 | 6 | |
| 8 | 2021 | 5 | |
| 9 | Chondrocyte ferroptosis contribute to the progression of osteoarthritisbreakdown → | 2020 | 309 |
| 10 | 2020 | 109 | |
| 11 | 2019 | 27 | |
| 12 | 2018 | 96 | |
| 13 | 2018 | 27 | |
| 14 | 2017 | 16 | |
| 15 | 2017 | 17 | |
| 16 | 2016 | 43 | |
| 17 | 2014 | 40 | |
| 18 | 2014 | 12 | |
| 19 | 2013 | 5 | |
| 20 | 2013 | 9 |
About Xudong Yao
Xudong Yao is a scholar working on Cancer Research, Rheumatology and Applied Microbiology and Biotechnology, having authored 35 papers that have together received 1.9k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (7 papers), Osteoarthritis Treatment and Mechanisms (6 papers), MicroRNA in disease regulation (4 papers), Cancer, Hypoxia, and Metabolism (4 papers), RNA modifications and cancer (4 papers), Bone Metabolism and Diseases (4 papers), Circular RNAs in diseases (3 papers) and Prostate Cancer Treatment and Research (3 papers). The work is most often cited by research in Cancer Research (613 citations), Rheumatology (465 citations) and Molecular Biology (1.1k citations). Xudong Yao has collaborated with scholars based in China, Germany and United States. Frequent co-authors include Fengjing Guo, Jiachao Guo, Xingzhi Jing, Kai Sun, Kai Sun, Yaping Ye, Genchun Wang, Jiamin Lin, Guohua Zhou and Shengnan Yu. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology and Life Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.